Compare BridgeBio Pharma Inc (BBIO) vs Global Payments Inc (GPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Global Payments Inc — how do they compare? BridgeBio Pharma Inc trades at $84.87 (market cap $16.46B), while Global Payments Inc trades at $76.2 (market cap $20.76B). The key difference: Global Payments Inc is the larger of the two by market cap, and Global Payments Inc pays a 1.32% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | GPN | |
|---|---|---|
Market Cap | $16.46B | $20.76B |
Sector | Health | Industrials |
52-Week High | $90.17 | $90.01 |
52-Week Low | $44.81 | $62.47 |
Enterprise Value | $18.02B | $38.48B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
GPN trades at $76.85, up 1.07% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $2.96, exceeding expectations, and maintains strong cash flow from operations at $2.66B in 2025. However, net income margin turned negative at -7.97% for 2026, reflecting profitability challenges amid rising debt levels, with debt-to-asset ratio increasing to 41.57% in 2025.
The outlook is mixed: analyst consensus is bullish with a $81.56 price target and 58% buy ratings, supported by AI-driven POS expansions and the Worldpay integration. Key risks include margin pressure from fintech competition and high leverage, which could constrain equity returns if revenue growth falters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
